Nintedanib | BIBF 1120;Intedanib | VEGFR | PDGFR | FGFR | AmBeed-信号通路专用抑制剂

首页 / / / / Nintedanib

尼达尼布 /Nintedanib {[allProObj[0].p_purity_real_show]}

货号：A181556 同义名： BIBF 1120;Intedanib

Nintedanib（BIBF 1120）是一种强效的三重血管激酶抑制剂，对VEGFR1/2/3、FGFR1/2/3和PDGFRα/β的IC50值分别为34 nM、13 nM、13 nM、69 nM、37 nM、108 nM、59 nM和65 nM。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Nintedanib 化学结构
CAS号：656247-17-5

Nintedanib 3D分子结构
CAS号：656247-17-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Nintedanib 纯度/质量文件产品仅供科研

货号：A181556 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

PDGFR 亚型比较
FGFR 亚型比较
VEGFR 亚型比较

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				98%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			VEGFR,mTOR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	98+%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	98%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FGFR ↓ ↑	FGFR1 ↓ ↑	FGFR2 ↓ ↑	FGFR3 ↓ ↑	FGFR4 ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ FGFR (Swiss 3T3), IC50: 12.3 μM					PDGFR	99%+
Pazopanib	+ FGFR, IC50: 140 nM						99%
Erdafitinib	✔					RET	99%+
Gambogenic acid	✔						98+%
Sulfatinib		+++ FGFR1, IC50: 15 nM					99+%
Nintedanib esylate		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM			98%
Zoligratinib		+++ FGFR1, IC50: 9.3 nM	+++ FGFR2, IC50: 7.6 nM	++ FGFR3, IC50: 22 nM	+ FGFR4, IC50: 290 nM		99%+
MK-2461		+ FGFR1, IC50: 65 nM	++ FGFR2, IC50: 39 nM	++ FGFR3, IC50: 50 nM			98%+
SU 5402		++ FGFR1, IC50: 30 nM					98%
Brivanib		+ FGFR1, IC50: 148 nM					99%+
Lucitanib		++ FGFR1, IC50: 17.5 nM	+ FGFR2, IC50: 82.5 nM				99%+
Ponatinib		++++ FGFR1, IC50: 2.2 nM					98%
PD-166866		+ FGFR1, IC50: 52.4 nM					98%
Narazaciclib		++ FGFR1, IC50: 26 nM				RET	99%+
Lactate		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		FLT3,c-Kit	85%
Lenvatinib mesylate		++ FGFR1, IC50: 46 nM				c-RET	99%
LY2874455		++++ FGFR1, IC50: 2.8 nM	++++ FGFR2, IC50: 2.6 nM	+++ FGFR3, IC50: 6.4 nM	+++ FGFR4, IC50: 6 nM		99%+
FIIN-2		+++ FGFR1, IC50: 3.09 nM	+++ FGFR2, IC50: 4.3 nM	++ FGFR3, IC50: 27 nM	++ FGFR4, IC50: 45.3 nM		98%
FIIN-3		+++ FGFR1, IC50: 13.1 nM	++ FGFR2, IC50: 21 nM	++ FGFR3, IC50: 31.4 nM	++ FGFR4, IC50: 35.3 nM		98%
Infigratinib		++++ FGFR1, IC50: 0.9 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3 (K650E), IC50: 4.9 nM FGFR3, IC50: 1.0 nM	+ FGFR4, IC50: 60 nM		99%+
Danusertib		++ FGFR1, IC50: 47 nM				RET	99%+
R1530		++ FGFR1, IC50: 28 nM					98%
ENMD-2076		+ FGFR1, IC50: 92.7 nM	+ FGFR2, IC50: 70.8 nM			FLT3,RET	98%
Dovitinib		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		FLT3,c-Kit	99%+
Sorafenib		+ FGFR1, IC50: 580 nM					99%
SSR128129E		+ FGFR1, IC50: 1.9 μM					99%+
AZD-4547		++++ FGFR1, IC50: 0.2 nM	++++ FGFR2, IC50: 2.5 nM	++++ FGFR3, IC50: 1.8 nM			98%
Lenvatinib		++ FGFR1, IC50: 46 nM				RET	98%
PD173074		++ FGFR1, IC50: ~25 nM					99%+
S49076		++ FGFR1, IC50: 18 nM	+++ FGFR2, IC50: 17 nM	+++ FGFR3, IC50: 15 nM			98%
Futibatinib		++++ FGFR1, IC50: 1.8 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3, IC50: 1.6 nM	+++ FGFR4, IC50: 3.7 nM		99%+
Ferulic Acid		+ FGFR1, IC50: 3.78 μM	+ FGFR2, IC50: 12.5 μM				98%
Nintedanib		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM	+ FGFR4, IC50: 610 nM		99+%
ASP5878		++++ FGFR1, IC50: 0.47 nM	++++ FGFR2, IC50: 0.6 nM	++++ FGFR3, IC50: 0.74 nM	+++ FGFR4, IC50: 3.5 nM		98%
PRN1371		++++ FGFR1, IC50: 0.6 nM	++++ FGFR2, IC50: 1.3 nM	+++ FGFR3, IC50: 4.1 nM	++ FGFR4, IC50: 19.3 nM		99%
Derazantinib		+++ FGFR1, IC50: 4.5 nM	++++ FGFR2, IC50: 1.8 nM	+++ FGFR3, IC50: 4.5 nM	++ FGFR4, IC50: 34 nM	RET	99%+
ODM-203		+++ FGFR1, IC50: 11 nM	+++ FGFR2, IC50: 16 nM	+++ FGFR3, IC50: 6 nM	++ FGFR4, IC50: 35 nM		99%+
Pemigatinib		++++ FGFR1, IC50: 0.4 nM	++++ FGFR2, IC50: 0.5 nM	++++ FGFR3, IC50: 1.2 nM	++ FGFR4, IC50: 30 nM		99%+
SKLB 610			✔			PDGFR	99%+
Alofanib			✔				99%+
Lirafugratinib			✔				98%
Masitinib mesylate				✔		FAK	99%+
BLU9931				+ FGFR3, IC50: 150 nM	+++ FGFR4, IC50: 3 nM		99%+
BO-264				✔			99%+
Fisogatinib					+++ FGFR4, IC50: 5 nM		99%+
H3B-6527					++++ FGFR4, IC50: <1.2 nM		99%+
Roblitinib					++++ FGFR4, IC50: 1.9 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	98%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Nintedanib 生物活性

靶点	VEGFR1 VEGFR1, IC50:34 nM VEGFR3 VEGFR3, IC50:13 nM VEGFR2 VEGFR2, IC50:13 nM PDGFRβ PDGFRβ, IC50:65 nM
描述	VEGF/VEGFR (vascular endothelial growth factor/vascular endothelial growth factor receptor) pathway plays a key role in tumor angiogenesis by promotion of vascular and lymphatic endothelial, as well as survival, and invasion, thus resulting in neovascularization, tumor growth and metastasis. In addition, blockade of additional proangiogenic receptor tyrosine kinases, including PDGFR and FGFR, may improve long-term clinical outcomes. BIBF 1120 is a multi-RTKs inhibitor with IC50 values of 13nM, 13nM , 16nM , 26nM , 34nM , 37nM , 59nM , 65nM , 69nM , 108nM for VEGFR2, VEGFR3, LCK, FLT3, VEGFR1, FGFR2, PDGFRα, PDGFRβ, FGFR1, FGFR3 (measured by enzymatic assays), less potent to Src, Lyn and FGFR4 with IC50 values of 156nM , 195nM and 610nM, respectively. Treatment with BIBF 1120 resulted in cell proliferation and apoptosis (EC50<10nM) in HUVECs, HSMECs, as well as the downstream p-MAPK and p-AKT (0.1-1μM). Daily oral treatment with BIBF 1120 at dose of 100mg/kg for 5 days reduced vessel density by 76% in FaDu xenografts, as well as markedly reduced both Meca 32–positive and PDGFRβ-positive cells predominantly in the intratumoral compartment. Once daily oral administration of BIBF 1120 at dose of 50mg/kg and 100mg/kg inhibited tumor growth both in a model of human head and neck small cell carcinoma (FaDu cells) and in a human renal cancer model (Caki-1 cells)^[1].
作用机制	BIBF 1120 is ATP-competitive proangiogenic receptor tyrosine kinase inhibitor, which can bound in the active site of the VEGFR-2.^[1]

Nintedanib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A549	2/5 μM	Function Assay	24 h	has a general EMT reversal effect	26061747
A549	0.01–5 μM	Function Assay	24 h	induces SFTPD mRNA expression dose dependently	25843005
A549	0.01–5 μM	Function Assay	72 h	enhances SP-D protein expression in a dose-dependent manner at concentrations of up to 5 μM	25843005
A549	5 μM	Function Assay	0-1 h	increases AP-1 activation after 30 min	25843005

Nintedanib 动物研究

Dose

Mice: 50 mg/kg^[2] (p.o.), 3 mg/kg - 100 mg/kg^[3] (p.o.); 5 mg/kg^[4] (i.p.)
Rat: 25 mg/kg - 100 mg/kg^[1] (p.o.)

Administration

p.o., i.p.

Pharmacokinetics

Animal	Mice^[5]	Rats^[5]	Monkeys^[5]
Dose	50 mg/kg	50 mg/kg (p.o.) 2 mg/kg (i.v.)	40 mg/kg (p.o., cynomolgus monkey) 5 mg/kg (i.v., cynomolgus monkey)
Administration	p.o.	p.o. i.v.	p.o. i.v.
MRT	5.19 h	3.25 h (i.v.)	3.82 h (i.v.)
F		11.9% (p.o.)	13.2% (p.o.)
T_1/2	5.15 h	3.95 h (i.v.)	5.95 h (i.v.)
AUC	2720 ng·h/ml	375 ng·h/ml (p.o.) 181 ng·h/ml (i.v.)	2390 ng·h/ml (p.o.) 2260 ng·h/ml (i.v.)
CL		202 ml/min/kg (i.v.)	37.5 ml/min/kg (i.v.)
C_max	547 ng/ml	105 ng/ml (p.o.) 124 ng/ml (i.v.)	175 ng/ml (p.o.) 1300 ng/ml (i.v.)
Protein bound (%)			92.9% (p.o.)
Protein binding (free drug %)	0.972	98.5% (p.o.)
Vss		41.2 L/kg (i.v.)	8.64 L/kg (i.v.)

Nintedanib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03361319	NSCLC, Recurrent ... 展开 >> Adenocarcinoma of Lung 收起 <<	Phase 1 Phase 2	Not yet recruiting	January 2022	-
NCT02863055	Malignant Pleural Mesothelioma	Phase 2	Recruiting	October 2020	Belgium ... 展开 >> UZ Antwerpen Recruiting Antwerpen, Belgium Contact: Jan Van Meerbeeck, prof UZ Gent Recruiting Gent, Belgium Contact: Veerle Surmont, Prof Italy Ospedale San Paolo Recruiting Milan, Italy Contact: Andrea Luciani, Dr United Kingdom Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital Recruiting Wythenshawe, Manchester, United Kingdom, M23 9LT Principal Investigator: Paul Taylor Royal Marsden Hospital Recruiting Chelsea, United Kingdom Contact: Sanjay Popat, Dr Royal Marsden Hospital - Kingston Recruiting Kingston, United Kingdom Contact: Sanjay Popat, Dr Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital Recruiting Sheffield, United Kingdom Contact: Robin Young, Dr NHS South Tyneside-South Tyneside District Hospital Recruiting South Shields, United Kingdom Contact: Rhona McMenemin, Dr Royal Marsden Hospital Recruiting Sutton, United Kingdom Contact: Sanjay Popat, Dr 收起 <<
NCT02597933	Scleroderma, Systemic	Phase 3	Completed	-	-

Nintedanib 参考文献

[1]Hilberg F, Roth GJ, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82.

[2]Roth GJ, Heckel A, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009 Jul 23;52(14):4466-80.

[3]Wollin L, Maillet I, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014 May;349(2):209-20.

[4]Öztürk Akcora B, Storm G, et al. Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Sci Rep. 2017 Mar 14;7:44545.

[5]Nintedanib

Nintedanib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.19mL

9.27mL

1.85mL

0.93mL

18.53mL

3.71mL

1.85mL

Nintedanib 技术信息

CAS号	656247-17-5
分子式	C₃₁H₃₃N₅O₄
分子量	539.62

别名	BIBF 1120;Intedanib
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 10 mg/mL(18.53 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+water 0.1 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03361319	NSCLC, Recurrent ... 展开 >> Adenocarcinoma of Lung 收起 <<	Phase 1 Phase 2	Not yet recruiting	January 2022	-
NCT02863055	Malignant Pleural Mesothelioma	Phase 2	Recruiting	October 2020	Belgium ... 展开 >> UZ Antwerpen Recruiting Antwerpen, Belgium Contact: Jan Van Meerbeeck, prof UZ Gent Recruiting Gent, Belgium Contact: Veerle Surmont, Prof Italy Ospedale San Paolo Recruiting Milan, Italy Contact: Andrea Luciani, Dr United Kingdom Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital Recruiting Wythenshawe, Manchester, United Kingdom, M23 9LT Principal Investigator: Paul Taylor Royal Marsden Hospital Recruiting Chelsea, United Kingdom Contact: Sanjay Popat, Dr Royal Marsden Hospital - Kingston Recruiting Kingston, United Kingdom Contact: Sanjay Popat, Dr Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital Recruiting Sheffield, United Kingdom Contact: Robin Young, Dr NHS South Tyneside-South Tyneside District Hospital Recruiting South Shields, United Kingdom Contact: Rhona McMenemin, Dr Royal Marsden Hospital Recruiting Sutton, United Kingdom Contact: Sanjay Popat, Dr 收起 <<
NCT02597933	Scleroderma, Systemic	Phase 3	Completed	-	-
NCT01770392	-		Completed	-	-
NCT02607722	-		Active, not recruiting	January 31, 2020	Japan ... 展开 >> Multiple Locations, Japan 收起 <<
NCT01770392	Healthy	Phase 1	Completed	-	Germany ... 展开 >> 1199.162.1 Boehringer Ingelheim Investigational Site Biberach, Germany 收起 <<
NCT02856425	Patients With Any Advanced Sol... 展开 >>id Tumors 收起 <<	Phase 1	Suspended(Safety event)	July 2026	France ... 展开 >> Gustave Roussy Villejuif, Val De Marne, France, 94805 收起 <<
NCT03710824	-		Not yet recruiting	January 13, 2021	-
NCT02452463	Radiation-Induced Pneumonitis ... 展开 >> Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 2	Recruiting	January 7, 2020	United States, New York ... 展开 >> Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Grace Dy 716-845-3099 Grace.Dy@RoswellPark.org Principal Investigator: Grace Dy United States, West Virginia West Virginia University Recruiting Morgantown, West Virginia, United States, 26506 Contact: Carloa Ross 304-581-1158 cjross@hsc.wvu.edu Principal Investigator: Malcom Mattes, MD 收起 <<
NCT03287947	Appendix Cancer	Phase 2	Recruiting	March 1, 2022	United States, North Carolina ... 展开 >> Levine Cancer Institute Recruiting Charlotte, North Carolina, United States, 28204 Contact: Nathan Thompson, RN 980-487-3241 Nathan.Thompson@carolinashealthcare.org 收起 <<
NCT02399215	Carcinoid Tumor ... 展开 >> Metastatic Carcinoid Tumor Neuroendocrine Neoplasm 收起 <<	Phase 2	Active, not recruiting	August 1, 2019	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT03513484	Acute Myeloid Leukemia With t(... 展开 >>9;11)(p22.3;q23.3); MLLT3-KMT2A Fibroblast Growth Factor Basic Form Measurement FLT3 Internal Tandem Duplication Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia 收起 <<	Phase 1	Recruiting	January 2021	United States, Illinois ... 展开 >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Jessica K. Altman 312-695-6180 j-altman@northwestern.edu Principal Investigator: Jessica K. Altman 收起 <<
NCT02730416	Endometrial Cancer	Phase 2	Recruiting	July 2022	Denmark ... 展开 >> NSGO Recruiting Copenhagen, Sjaelland, Denmark, 2100 Contact: Mette Berensen, RN mette.berensen.02@regionh.dk 收起 <<
NCT02531737	Lung Neoplasms	Phase 2	Recruiting	January 2019	France ... 展开 >> CH de Beauvais Recruiting Beauvais, France Contact: Jacky Crequet, MD 33.3 44 11 22 23 Jacky.crequit@wanadoo.fr Sub-Investigator: Jacky crequet, MD Ch de Beauvais Recruiting Beauvais, France Principal Investigator: Jacky CREQUIT, MD CHU Brest Recruiting Brest, France Contact: G. ROBINET, MD Principal Investigator: G ROBINET, MD Service de Pneumologie Recruiting Créteil, France Contact: Isabelle Monnet, MD 33.1 45 17 50 14 Isabelle.Monnet@chicreteil.fr Principal Investigator: Isabelle Monnet, MD Service de Pneumologie Recruiting Gap, France Contact: P Thomas, MD 33.4 92 40 61 26 pneumologie@ch-gap.fr Principal Investigator: P Thomas, MD CHU de Limoges Recruiting Limoges, France, 87000 Contact: A. Vergnenegre, MD alain.vergnenegre@unilim.fr Principal Investigator: B. Melloni, MD Principal Investigator: A. Vergnenegre, MD CH de Bretagne Sud Recruiting LOrient, France Contact: Regine LAMY, MD Principal Investigator: Regine LAMY, MD Centre Hospitalier F. Quesnay Recruiting Mantes La Jolie, France, 78200 Contact: JB. Auliac, MD 33 (0)1 34 97 40 70 j-b.auliac@ch-mantes-la-jolie.rss.fr Principal Investigator: JB. Auliac, MD AP-HM Recruiting Marseille, France Principal Investigator: Fabrice BARLESI, MD Institut Paoli-Calmettes Recruiting Marseille, France Contact: Anne MADROSZYK, MD Principal Investigator: Anne MADROSZYK, MD Instiut de Cancérologie Recruiting Saint Etienne, France Principal Investigator: Pierre FOURNEL, MD Service de Pneumologie Recruiting Villefranche, France Contact: L falchero, MD 33.4 74 09 27 23 lfalchero@ch-villefranche.fr Principal Investigator: L Falchero, MD 收起 <<
NCT02665143	Relapsed/Refractory Acute Myel... 展开 >>oid Leukemia 收起 <<	Phase 1 Phase 2	Recruiting	December 2019	United States, Connecticut ... 展开 >> Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Rebecca Lilian 203-737-8358 rebecca.lilian@yale.edu United States, Tennessee Vanderbilt Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Channing V Dudley, RN, MSN 615-875-5503 channing.v.dudley@vanderbilt.edu Principal Investigator: Stephen Strickland, MD 收起 <<
NCT03377023	Non Small Cell Lung Cancer ... 展开 >> Lung Cancer, Nonsmall Cell Non Small Cell Lung Cancer Metastatic 收起 <<	Phase 1 Phase 2	Recruiting	February 2021	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez 813-745-6636 germaine.gonzalezvazquez@moffitt.org Contact: Jhanelle E. Gray, M.D. 813-745-6895 jhanelle.gray@moffitt.org 收起 <<
NCT02149108	Colorectal Neoplasms	Phase 3	Completed	-	-
NCT01658462	Breast Cancer	Phase 2	Unknown	December 2016	France ... 展开 >> CHU Amiens- Hôpital Sud Amiens, France, 80 054 Hôpital Privé les Bonnettes Arras, France, 62000 Centre Pierre Curie Beuvry, France, 62660 CH Compiègne-Noyon Compiègne, France, 60200 Centre Léonard de Vinci Dechy, France, 59 187 Centre Oscar Lambret Lille, France, 59 020 Polyclinique de Limoges - site Chénieux Limoges, France, 87039 Institut Jean Godinot Reims, France, 51056 CMCO de la Côte d'Opale Saint Martin les Boulogne, France, 62280 Hôpital Bretonneau Tours, France, 37044 Nouvelle Clinique des Dentellières Valenciennes, France, 59300 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54 500 收起 <<
NCT02149108	-		Completed	-	-
NCT02572752	-		Completed	-	-
NCT02572752	Healthy	Phase 1	Completed	-	Germany ... 展开 >> Boehringer Ingelheim Investigational Site Biberach, Germany 收起 <<
NCT01907100	Mesothelioma	Phase 3	Completed	-	-
NCT02191865	Hepatic Insufficiency	Phase 1	Completed	-	Germany ... 展开 >> 1199.200.49001 Boehringer Ingelheim Investigational Site Kiel, Germany 收起 <<
NCT02619162	Breast Cancer	Phase 1	Unknown	April 2018	Spain ... 展开 >> Hospital Universitario de Fuenlabrada Recruiting Fuenlabrada, Madrid, Spain, 28942 Contact: Miguel Angel Quintela, PhD +34-91.732.80.00 ext 2930 mquintela@cnio.es Contact: Berta Nasarre +34-91.600.65.84 bnasarre@ext.cnio.es Principal Investigator: Miguel Quintela, PhD Sub-Investigator: Juan Victor Apala Sub-Investigator: Juan Antonio Guerra Sub-Investigator: Diego Malón Sub-Investigator: Laura Rodríguez Hospital de La Princesa Recruiting Madrid, Spain, 28006 Contact: Ramón Colomer +34.91.5202276 rcolomer@seom.org Contact: Anabel Ballestero +34.91.5202276 Principal Investigator: Ramón Colomer, PhD MD Anderson Cancer Center Withdrawn Madrid, Spain, 28033 Clínica Quirón Recruiting Madrid, Spain, 28223 Contact: Miguel Quintela, PhD 91.732.8000 ext 2930 mquintela@cnio.es Principal Investigator: Miguel Quintela, PhD 收起 <<
NCT02191865	-		Completed	-	-
NCT00806819	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	-
NCT00806819	-		Completed	-	-
NCT02308553	Cutaneous Malignant Melanoma	Phase 1 Phase 2	Recruiting	June 2018	Germany ... 展开 >> University Hospital Essen Recruiting Essen, NRW, Germany, 45147 Contact: Dirk Schadendorf, Prof. Dr. +49-201- 723 ext 4342 dirk.schadendorf@uk-essen.de Principal Investigator: Dirk Schadendorf, Prof. Dr. Elbeklinikum Buxtehude Recruiting Buxtehude, Germany, 21614 Contact: Peter Mohr, Dr. med. peter.mohr@elbekliniken.de Principal Investigator: Peter Mohr, Dr. med. SRH Wald-Klinikum Gera Not yet recruiting Gera, Germany, 07548 Contact: Martin Kaatz, PD Dr. martin.kaatz@wkg.srh.de Principal Investigator: Martin Kaatz, PD Dr. National Centre for Tumour Diseases (NCT) Recruiting Heidelberg, Germany, 69120 Contact: Jessica Hassel, Dr. med. jessica.hassel@med.uni-heidelberg.de Principal Investigator: Jessica Hassel, Dr. med. Universitätsklinikum des Saarlandes Not yet recruiting Homburg, Germany, 66421 Contact: Claudia Pföhler, PD Dr. claudia.pfoehler@uks.eu Principal Investigator: Claudia Pföhler, PD Dr. Klinikum der Stadt Ludwigshafen am Rhein gGmbH Recruiting Ludwigshafen, Germany, 67063 Contact: Edgar Dippel, Prof. Dr. dippele@klilu.de Principal Investigator: Edgar Dippel, Prof. Dr. Universitätsklinikum Schleswig-Holstein, Campus Lübeck Not yet recruiting Lübeck, Germany, 23538 Contact: Patrick Terheyden, PD Dr. patrick.terheyden@uksh.de Principal Investigator: Patrick Terheyden, PD Dr. University Hospital München Recruiting München, Germany, 80337 Contact: Carola Berking, Prof. Dr. carola.berking@med.uni-muenchen.de Principal Investigator: Carola Berking, Prof. Dr. Fachklinik Hornheide Recruiting Münster, Germany, 48157 Contact: Michael Fluck, Dr. med. michael.fluck@fachklinik-hornheide.de Principal Investigator: Michael Fluck, Dr. med. 收起 <<
NCT02234596	Esophagogastric Adenocarcinoma	Phase 2	Active, not recruiting	September 2019	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States 收起 <<
NCT02300298	-		Completed	-	-
NCT02393755	Colon Adenocarcinoma ... 展开 >> Rectal Adenocarcinoma Recurrent Colon Carcinoma Recurrent Rectal Carcinoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer 收起 <<	Phase 2	Active, not recruiting	January 1, 2019	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01417156	Pulmonary Fibrosis	Phase 2	Completed	-	Japan ... 展开 >> Boehringer Ingelheim Investigational Site Himeji, Hyogo, Japan Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan Boehringer Ingelheim Investigational Site Seto, Aichi, Japan Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan 收起 <<
NCT02866370	Ovarian Clear Cell Carcinoma ... 展开 >> Endometrial Clear Cell Carcinoma 收起 <<	Phase 2	Recruiting	March 2021	United Kingdom ... 展开 >> Beatson West of Scotland Cancer Centre Recruiting Glasgow, Lanarkshire, United Kingdom, G12 0YN Contact: Ros Glasspool Principal Investigator: Ros Glasspool Sub-Investigator: Iain McNeish Ninewells Hospital Recruiting Dundee, Tayside, United Kingdom Principal Investigator: Michelle Ferguson Clatterbridge Cancer Centre Recruiting Liverpool, Wirral, United Kingdom Principal Investigator: Rosemary Lord Belfast City Hospital (Northern Ireland Cancer Centre) Recruiting Belfast, United Kingdom Principal Investigator: Sarah McKenna Bristol Heamatology and Cancer Centre Recruiting Bristol, United Kingdom Principal Investigator: Axel Walther Velindre Hospital Recruiting Cardiff, United Kingdom Principal Investigator: Rachel Jones Kent & Canterbury Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters Queen Elizabeth Queen Mother Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters William Harvey Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters St James Hospital Recruiting Leeds, United Kingdom Principal Investigator: Geoff Hall Guy's Hosital Recruiting London, United Kingdom Principal Investigator: Ana Montes Royal Marsden Hospital Recruiting London, United Kingdom Principal Investigator: Susannah Bannerjee St Bartholomew's Hospital Not yet recruiting London, United Kingdom Principal Investigator: Melanie Powell University College London Hospital Not yet recruiting London, United Kingdom Principal Investigator: Jonathan Ledermann The Christie Hospital Recruiting Manchester, United Kingdom Principal Investigator: Andrew Clamp Great Western Hospital Recruiting Swindon, United Kingdom Principal Investigator: Omar Khan Musgrove Park Hospital Recruiting Taunton, United Kingdom Principal Investigator: Clare Barlow 收起 <<
NCT00514683	Pulmonary Fibrosis	Phase 2	Completed	-	-
NCT02300298	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Japan ... 展开 >> 1199.90.81001 Boehringer Ingelheim Investigational Site Chiba , Kashiwa, Japan 1199.90.81003 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan 1199.90.81007 Boehringer Ingelheim Investigational Site Osaka, Osakasayama, Japan 1199.90.81006 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1199.90.81004 Boehringer Ingelheim Investigational Site Shizuoka, Sunto-gun, Japan 1199.90.81002 Boehringer Ingelheim Investigational Site Tokyo, Chuo, Japan 收起 <<
NCT01417156	-		Completed	-	-
NCT02579603	-		Completed	-	-
NCT02667704	Healthy	Phase 1	Completed	-	Germany ... 展开 >> Boehringer Ingelheim Investigational Site Biberach, Germany 收起 <<
NCT02667704	-		Completed	-	-
NCT00514683	-		Completed	-	-
NCT01225887	Endometrial Adenocarcinoma ... 展开 >> Endometrial Clear Cell Adenocarcinoma Endometrial Mucinous Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Squamous Cell Carcinoma Endometrial Transitional Cell Carcinoma Endometrial Undifferentiated Carcinoma Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm Recurrent Uterine Corpus Carcinoma 收起 <<	Phase 2	Completed	-	-
NCT02579603	Idiopathic Pulmonary Fibrosis	Phase 4	Completed	-	United States, Connecticut ... 展开 >> Western CT Medical Group, P.C. Danbury, Connecticut, United States, 06810 United States, Louisiana Tulane University Hospital and Clinic New Orleans, Louisiana, United States, 70112 United States, Minnesota Minnesota Lung Center Minneapolis, Minnesota, United States, 55407 United States, Missouri The Lung Research Center, LLC Chesterfield, Missouri, United States, 63017 United States, South Carolina Lowcountry Lung and Crit Care Charleston, South Carolina, United States, 29406 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232-5735 Canada, British Columbia St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Concordia Hospital Winnipeg, Manitoba, Canada, R2K 3S8 France HOP Avicenne Bobigny, France, 93009 HOP de la Cavale Blanche Brest, France, 29609 HOP Louis Pradel Bron cedex, France, 69677 HOP Calmette Lille, France, 59037 HOP Pasteur Nice, France, 06001 HOP Bichat Paris, France, 75018 HOP Pontchaillou Rennes, France, 35033 Germany Klinik Donaustauf Donaustauf, Germany, 93093 Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH Essen, Germany, 45239 Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg Heidelberg, Germany, 69126 Italy A.O.U. Policlinico Vittorio Emanuele Catania, Italy, 95124 Osp. S. Giuseppe Fatebenefratelli Milano, Italy, 20123 A.O.U. Senese Policlinico Santa Maria alle Scotte Siena, Italy, 53100 Netherlands Sint Antonius Ziekenhuis Nieuwegein, Netherlands, 3435 CM Erasmus Medisch Centrum Rotterdam, Netherlands, 3015 CE 收起 <<
NCT02009579	Uterine Cervical Neoplasms	Phase 2	Recruiting	July 2020	Belgium ... 展开 >> CHU Saint-Pierre Active, not recruiting Bruxelles, Belgium Institut Jules Bordet Recruiting Bruxelles, Belgium Grand Hopital de Charleroi Active, not recruiting Charleroi, Belgium UZ Antwerpen Active, not recruiting Edegem, Belgium AZ Groeninge Recruiting Kortrijk, Belgium UZ Leuven Recruiting Leuven, Belgium, 3000 Principal Investigator: Ignace Vergote, MD CHR Citadelle Recruiting Liege, Belgium CHU de Liège Recruiting Liège, Belgium, 4000 Contact: Christine Gennigens, MD Clinique et maternite St. Elisabeth Recruiting Namur, Belgium Cliniques Universitaires mont godinne Active, not recruiting Yvoir, Belgium Germany Charité Med Uni Berlin Recruiting Berlin, Germany Contact: Radoslav Chekerov, MD Universitätsklinikum Carl Gustav Carus Dresden Recruiting Dresden, Germany Contact: Pauline Wimberger, MD Kliniken Essen Mitte Active, not recruiting Essen, Germany Georg-August University Göttingen Active, not recruiting Gottingen, Germany Medical University Greifswald Recruiting Greifswald, Germany Contact: Alexander Mustea, MD University Tübingen Recruiting Tubingen, Germany Contact: Andreas Hartkopf, MD Italy Centro Riferimento Oncologico Not yet recruiting Aviano, Italy Contact: Roberto Sorio, MD Spedali Civili Not yet recruiting Brescia, Italy Contact: Germana Tognon, MD Azienda Ospedaliera Cannizzaro Not yet recruiting Catania, Italy Contact: Paolo Scollo, MD National Cancer Institute Recruiting Milano, Italy Contact: Ketta Lorusso, MD Istituto Nazionale Tumori-Pascale Naples Active, not recruiting Naples, Italy Padova Istituti Oncologico Veneto Not yet recruiting Padova, Italy Contact: Maria Nicoletto, MD University Pisa Not yet recruiting Pisa, Italy Contact: Angiolo Gadducci, MD AUSL Reggio Emilia Not yet recruiting Reggio Emilia, Italy Contact: allesandra bologna, MD Poloclinico A Gemelli Not yet recruiting Rome, Italy Contact: Giovanni Scambia, MD Mauriziano -Torino Active, not recruiting Torino, Italy S. Anna Torino Recruiting Torino, Italy Contact: Paolo Zola, MD Spain Hospital Provincial Reina Sofia Recruiting Córdoba, Spain, 14004 Contact: Maria Jesús Rubio, MD H. Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Eva Maria Guerra, MD Hospital Clinico San Carlos Recruiting Madrid, Spain, 28040 Contact: Antonio Casado, MD Hospital Universitario Morales Meseguer Recruiting Murcia, Spain, 30008 Contact: Helena Garcia, MD Hospital Son Llatzer Recruiting Palma Mallorca, Spain, 07198 Contact: Isabel Bover, MD 收起 <<
NCT03062943	Lymphangioleiomyomatosis	Phase 2	Recruiting	October 2020	Italy ... 展开 >> Pneumology unit Recruiting Milan, Italy, 20123 Contact: Sergio A Harari, MD +39 02 55 40 4580 sergioalfonso.harari@multimedica.it Contact: Mara Cattaeno +39 02 55 40 4127 mara.cattaneo@multimedica.it Principal Investigator: Sergio A Harari, MD Sub-Investigator: Olga Torre, MD Sub-Investigator: Roberto Cassandro, MD 收起 <<
NCT00706628	Prostatic Neoplasms	Phase 2	Completed	-	United Kingdom ... 展开 >> 1239.3.4402 Boehringer Ingelheim Investigational Site Belfast, United Kingdom 1239.3.4406 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1239.3.4408 Boehringer Ingelheim Investigational Site Brighton, United Kingdom 1239.3.4409 Boehringer Ingelheim Investigational Site Cheltenham, United Kingdom 1239.3.4405 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1239.3.4403 Boehringer Ingelheim Investigational Site Newcastle Upon Tyne, United Kingdom 1239.3.4411 Boehringer Ingelheim Investigational Site Southampton, United Kingdom 1239.3.4401 Boehringer Ingelheim Investigational Site Sutton, United Kingdom 1239.3.4410 Boehringer Ingelheim Investigational Site Truro, United Kingdom 收起 <<
NCT00706628	-		Completed	-	-
NCT00987935	Carcinoma, Hepatocellular	Phase 2	Completed	-	Korea, Republic of ... 展开 >> 1199.39.82001 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82002 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82003 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82004 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82005 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82006 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Taiwan 1199.39.88606 Boehringer Ingelheim Investigational Site Changhua, Taiwan 1199.39.88609 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88610 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88605 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1199.39.88608 Boehringer Ingelheim Investigational Site Tainan City, Taiwan 1199.39.88602 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1199.39.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88603 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88604 Boehringer Ingelheim Investigational Site Taoyuan County, Taiwan 1199.39.88607 Boehringer Ingelheim Investigational Site Yunlin County, Taiwan 收起 <<
NCT00710762	-		Completed	-	-
NCT02299141	Carcinoma, Non-Small-Cell Lung... 展开 >> Non-Small Cell Lung Cancer Nonsmall Cell Lung Cancer 收起 <<	Phase 1	Recruiting	February 28, 2020	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Ramaswamy Govindan, M.D. 314-362-5654 rgovindan@wustl.edu Contact: Cindy Fogal 314-362-1518 clfogal@wustl.edu Principal Investigator: Ramaswamy Govindan, M.D. Sub-Investigator: Saiama Waqar, M.D. Sub-Investigator: Daniel Morgensztern, M.D. Sub-Investigator: Ticiana Leal, M.D. United States, Wisconsin University of Wisconsin Clinical Science Center Recruiting Madison, Wisconsin, United States, 53705 Contact: Ticiana Leal, M.D. 608-265-1700 tbleal@medicine.wisc.edu Principal Investigator: Ticiana Leal, M.D. Sub-Investigator: Toby C Campbell, M.D. Sub-Investigator: Anne Traynor, M.D. Sub-Investigator: Justine Yang Bruce, M.D. Sub-Investigator: Rosemary Sahagian Neider, N.P. 收起 <<
NCT01225887	-		Completed	-	-
NCT00710762	Ovarian Neoplasms	Phase 2	Completed	-	United Kingdom ... 展开 >> 1199.9.4413 Boehringer Ingelheim Investigational Site Burton on Trent, United Kingdom 1199.9.4412 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1199.9.4407 Boehringer Ingelheim Investigational Site Creigiau, Cardiff, United Kingdom 1199.9.4410 St James's University Hospital Leeds, United Kingdom 1199.9.4401 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4404 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4409 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4411 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4406 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1199.9.4402 Boehringer Ingelheim Investigational Site Northwood, United Kingdom 1199.9.4405 Boehringer Ingelheim Investigational Site Sutton, United Kingdom 收起 <<
NCT00801294	Colorectal Neoplasms	Phase 2	Completed	-	France ... 展开 >> 1239.2.3305A clinique Saint Jean Lyon, France 1239.2.3305B Cabinet Médical Lyon, France 1239.2.3301A Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301B Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301C Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301D Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301E Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301F Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301G Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301H Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301I Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301J Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3301K Hôpital Saint Antoine Paris Cedex 12, France 1239.2.3302A Hôpital Tenon Paris Cedex 20, France 1239.2.3302B Hôpital Tenon Paris Cedex 20, France 1239.2.3304A Hôpital Robert Debré Reims Cedex, France 1239.2.3304B Hôpital Robert Debré Reims Cedex, France 1239.2.3304C Hôpital Robert Debré Reims Cedex, France 1239.2.3303A Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303B Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303C Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303D Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303E Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303F Institut Gustave Roussy Villejuif Cedex, France 收起 <<
NCT02808247	Sarcoma, Soft Tissue	Phase 2	Recruiting	January 2022	Belgium ... 展开 >> Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet Recruiting Brussels, Belgium, 1000 Contact: Gil Thierry +32 25413188 thierry.gil@bordet.be Cliniques Universitaires Saint-Luc (121) Recruiting Brussels, Belgium Contact: Filomena Mazzeo Filomena.Mazzeo@uclouvain.be U.Z. Leuven - Campus Gasthuisberg (147) Recruiting Leuven, Belgium Contact: Patrick Schöffski patrick.schoffski@uzleuven.be France Institut Bergonie Recruiting Bordeaux, France, 33076 Contact: Antoine Italiano a.italiano@bordeaux.unicancer.fr Centre Leon Berard (227) Recruiting Lyon, France Contact: Jean-Yves Blay jean-yves.blay@lyon.unicancer.fr Gustave Roussy (225) Recruiting Villejuif, France Contact: Olivier Mir olivier.mir@gustaveroussy.fr Lithuania Vilnius University Hospital Santariskiu Santaros Clinics Klinikos (9453) Recruiting Vilnius, Lithuania, 08661 Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (301) Recruiting Amsterdam, Netherlands, 1066 Leiden University Medical Centre (310) Recruiting Leiden, Netherlands, 2300 Poland Maria Sklodowska-Curie Memorial Cancer Centre Recruiting Warsaw, Poland, 02 781 Contact: Piotr Rutkowski rutkowskip@coi.waw.pl Spain Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) Recruiting Barcelona, Spain, 08916 Contact: Anna Estival estivalanna@gmail.com Hospital Universitario San Carlos (366) Recruiting Madrid, Spain, 28040 United Kingdom Royal Marsden Hospital - Chelsea, London (613) Recruiting London, United Kingdom, SW3 6JJ 收起 <<
NCT02225405	Stage IB Non-Small Cell Lung C... 展开 >>arcinoma AJCC v7 Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 收起 <<	Phase 1	Active, not recruiting	April 30, 2020	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02568449	Recurrent Pleural Malignant Me... 展开 >>sothelioma Stage IV Pleural Mesothelioma 收起 <<	Phase 2	Recruiting	January 1, 2018	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Not yet recruiting Sacramento, California, United States, 95817 Contact: David R. Gandara 916-734-8452 david.gandara@ucdmc.ucdavis.edu Principal Investigator: David R. Gandara United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Gregory P. Kalemkerian 734-615-4762 kalemker@umich.edu Principal Investigator: Gregory P. Kalemkerian, M.D. Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Antoinette J. Wozniak 313-576-8752 wozniakt@karmanos.org Principal Investigator: Antoinette J. Wozniak, M.D. Sub-Investigator: Shirsh Gadgeel, M.D. Sub-Investigator: Ammar Sukari, M.D. United States, New York Memorial Sloan Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Contact: Marjorie G. Zauderer, M.D. 646-888-4201 zauderem@mskcc.org Principal Investigator: Marjorie G. Zauderer, M.D. 收起 <<
NCT01362361	Colorectal Cancer	Phase 2	Unknown	December 2013	Germany ... 展开 >> Universitätsklinikum Halle Recruiting Halle, Sachsen-Anhalt, Germany, 06120 Contact: Thomas Seufferlein, MD Principal Investigator: Thomas Seufferlein, MD Sub-Investigator: Thomas J. Ettrich, MD Schwerpunktpraxis für Hämatologie und Onkologie Bottrop und Dorsten Recruiting Bottrop, Germany Principal Investigator: Carla V. Hannig, MD Universitätsklinikum Greifswald -Klinik für Innere Medizin A Recruiting Greifswald, Germany Principal Investigator: Julia Mayerle, MD Gemeinschaftspraxis und Tagesklinik Onkologie und Gastroenterologie - Halle Recruiting Halle, Germany Principal Investigator: Stefanie Frank-Gleich, MD Klinikum Karlsruhe, Medizinische Klinik III Recruiting Karlsruhe, Germany Principal Investigator: Margarethe Schmier, MD Kliniken der Stadt Köln gGmbH - Krankenhaus Holweide Recruiting Köln, Germany Principal Investigator: Claudia Lang, MD Universitätsmedizin Mannheim - TTZ am Interdisziplinären Tumorzentrum Recruiting Mannheim, Germany Principal Investigator: Ralf Hofheinz, MD Joh. Wesling Klinikum Minden Recruiting Minden, Germany Principal Investigator: Hans-Joachim Tischler, MD Stauferklinikum Schwäbisch Gmünd - Mutlangen - Zentrum Innere Medizin Recruiting Mutlangen, Germany Principal Investigator: Holger Hebart, MD Klinikum der Universität München-Großhadern - Medizinische Klinik und Poliklink III Recruiting München, Germany Principal Investigator: Volker Heinemann, MD Leopoldina-Krankenhaus Schweinfurt - Medizinische Klinik 2 Recruiting Schweinfurt, Germany Principal Investigator: Stephan Kanzler, MD Universitätsklinikum Ulm - Klinik für Innere Medizin I Recruiting Ulm, Germany Principal Investigator: Götz von Wichert, MD 收起 <<
NCT01948141	Recurrent Non-small Cell Lung ... 展开 >>Cancer Squamous Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 收起 <<
NCT00987935	-		Completed	-	-
NCT00715403	Neoplasms	Phase 1	Completed	-	France ... 展开 >> 1199.16.3306A Boehringer Ingelheim Investigational Site Bordeaux cedex, France 1199.16.3311A Boehringer Ingelheim Investigational Site Clichy Cedex, France 1199.16.3311B Boehringer Ingelheim Investigational Site Clichy Cedex, France 1199.16.3313A Boehringer Ingelheim Investigational Site Paris Cedex 10, France 1199.16.3313E Boehringer Ingelheim Investigational Site Paris Cedex 10, France 1199.16.3302A Boehringer Ingelheim Investigational Site Paris cedex 15, France 1199.16.3312A Boehringer Ingelheim Investigational Site Paris, France Germany 1199.16.49001 Boehringer Ingelheim Investigational Site Freiburg/Breisgau, Germany 1199.16.49004 Boehringer Ingelheim Investigational Site Grosshansdorf, Germany 1199.16.49008 Boehringer Ingelheim Investigational Site Tübingen, Germany 1199.16.49005 Boehringer Ingelheim Investigational Site Wiesbaden, Germany 收起 <<
NCT01015118	Ovarian Neoplasms ... 展开 >> Peritoneal Neoplasms 收起 <<	Phase 3	Completed	-	-
NCT02598193	-		Completed	-	-
NCT01015118	-		Completed	-	-
NCT01948141	-		Completed	-	-
NCT01004003	Carcinoma, Hepatocellular	Phase 2	Completed	-	Austria ... 展开 >> 1199.37.43001 Boehringer Ingelheim Investigational Site Wien, Austria 1199.37.43002 Boehringer Ingelheim Investigational Site Wien, Austria France 1199.37.33001 Boehringer Ingelheim Investigational Site Paris, France 1199.37.33002 Boehringer Ingelheim Investigational Site Paris, France Germany 1199.37.49008 Boehringer Ingelheim Investigational Site Berlin, Germany 1199.37.49009 Boehringer Ingelheim Investigational Site Erlangen, Germany 1199.37.49002 Boehringer Ingelheim Investigational Site Freiburg, Germany 1199.37.49001 Boehringer Ingelheim Investigational Site Hannover, Germany 1199.37.49010 Boehringer Ingelheim Investigational Site Heidelberg, Germany 1199.37.49005 Boehringer Ingelheim Investigational Site Jena, Germany 1199.37.49004 Boehringer Ingelheim Investigational Site Magdeburg, Germany 1199.37.49003 Boehringer Ingelheim Investigational Site München, Germany 1199.37.49006 Boehringer Ingelheim Investigational Site Tübingen, Germany Hungary 1199.37.36001 Boehringer Ingelheim Investigational Site Debrecen, Hungary Netherlands 1199.37.31002 Boehringer Ingelheim Investigational Site Leiden, Netherlands 1199.37.31001 Boehringer Ingelheim Investigational Site Utrecht, Netherlands Poland 1199.37.48002 Boehringer Ingelheim Investigational Site Olsztyn, Poland 1199.37.48003 Boehringer Ingelheim Investigational Site Warsaw, Poland 1199.37.48001 Boehringer Ingelheim Investigational Site Warszawa, Poland Romania 1199.37.40002 Boehringer Ingelheim Investigational Site Bucharest, Romania 1199.37.40003 Boehringer Ingelheim Investigational Site Cluj-Napoca, Romania United Kingdom 1199.37.44001 Boehringer Ingelheim Investigational Site Edgbaston, Birmingham, United Kingdom 1199.37.44005 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1199.37.44008 Boehringer Ingelheim Investigational Site Liverpool, United Kingdom 1199.37.44002 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44003 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44006 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1199.37.44004 Boehringer Ingelheim Investigational Site Nottingham, United Kingdom 收起 <<
NCT00715403	-		Completed	-	-
NCT00904839	Colorectal Neoplasms	Phase 2	Completed	-	-
NCT01004003	-		Completed	-	-
NCT02598193	Idiopathic Pulmonary Fibrosis	Phase 4	Completed	-	-
NCT01251484	Recurrent Glioblastoma	Phase 2	Completed	-	Denmark ... 展开 >> Rigshospitalet Copenhagen, Denmark, 2100 收起 <<
NCT00904839	-		Completed	-	-
NCT00730821	Neoplasms	Phase 1	Completed	-	United States, Arizona ... 展开 >> 1239.1.3 Boehringer Ingelheim Investigational Site Scottsdale, Arizona, United States United States, Florida 1239.1.1 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Michigan 1239.1.2 Boehringer Ingelheim Investigational Site Detroit, Michigan, United States United States, Nebraska 1239.1.4 Boehringer Ingelheim Investigational Site Omaha, Nebraska, United States 收起 <<
NCT02902484	Cancer of Pancreas	Phase 1 Phase 2	Recruiting	September 2020	United States, Texas ... 展开 >> University of Texas Southwestern Medical Center Recruiting Dallas, Texas, United States, 75063 Contact: Silvia Pilarski, RN 214-648-5919 Silvia.Pilarski@UTSouthwestern.edu Principal Investigator: Muhammad Beg, MD 收起 <<
NCT01484080	Breast Cancer	Phase 1 Phase 2	Completed	-	Spain ... 展开 >> Hospital Universitari de Bellvitge Hospitalet de Llobregat, Barcelona, Spain, 08907 Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain, 28942 MD Anderson Cancer Centre Madrid Madrid, Spain, 28033 收起 <<
NCT02182258	Healthy	Phase 1	Completed	-	-
NCT02182193	Healthy	Phase 1	Completed	-	-
NCT01136174	-		Completed	-	-
NCT02182050	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	-
NCT01170065	Pulmonary Fibrosis	Phase 2	Completed	-	-
NCT00979576	Carcinoma, Non-Small-Cell Lung	Phase 1	Terminated	-	Japan ... 展开 >> 1199.28.003 Boehringer Ingelheim Investigational Site Chiba,Kashiwa, Japan 1199.28.002 Boehringer Ingelheim Investigational Site Miyakojima-ku, Osaka, Japan 1199.28.001 Boehringer Ingelheim Investigational Site Osaka-Sayama, Osaka, Japan 收起 <<
NCT01788982	Medullary Thyroid Cancer (MTC)... 展开 >> Differentiated Thyroid Cancer (DTC) 收起 <<	Phase 2	Active, not recruiting	December 2018	Belgium ... 展开 >> A.Z. St. Jan Brugge, Belgium, 8000 Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet Brussels, Belgium, 1000 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 Universitair Ziekenhuis Antwerpen Edegem, Antwerpen, Belgium, 2650 Universitair Ziekenhuis Gent Gent, Belgium, 9000 U.Z. Leuven - Campus Gasthuisberg Leuven, Belgium, 3000 Denmark Odense University Hospital Odense, Denmark, 5000 France CHU d'Angers Angers, France, 49933 Institut Bergonie Bordeaux, France, 33076 Centre Regional Francois Baclesse Caen, France, 14076 Centre Georges-Francois-Leclerc Dijon, France, 21079 Centre Leon Berard Lyon, France, 69008 Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis Paris, France, 75475 Assistance Publique - Hopitaux de Paris - La Pitié Salpétrière Paris, France, 75651 Centre Jean Godinot Reims, France, 51056 Institut Gustave Roussy Villejuif, France Germany Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern Munich, Germany, DE 81377 Universitaetsklinikum Wuerzburg Wuerzburg, Germany, DE 97080 Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy Azienda Ospedaliera Universitaria "Federico II" Napoli, Italy, 80131 Netherlands University Medical Center Groningen Groningen, Netherlands, 9713 Leiden University Medical Centre Leiden, Netherlands, 2300 Radboud University Medical Center Nijmegen Nijmegen, Netherlands, 6500 Poland Maria Sklodowska-Curie Memorial Cancer Centre Warsaw, Poland, PL 02 781 Spain Hospital General Vall D'Hebron Barcelona, Spain, ES 08035 United Kingdom Royal Marsden Hospital - Sutton, Surrey Sutton, Surrey, United Kingdom, SM2 5PT NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital Glasgow, United Kingdom, G12 0YN 收起 <<
NCT00979576	-		Terminated	-	-
NCT01488344	Acute Myeloid Leukemia	Phase 1 Phase 2	Unknown	-	Germany ... 展开 >> Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A Münster, Germany, 48149 收起 <<
NCT03283007	Lung-transplant Recipients	Phase 3	Not yet recruiting	May 2022	-
NCT03562416	Idiopathic Pulmonary Fibrosis ... 展开 >> Lung Transplant; Complications 收起 <<	Phase 2	Not yet recruiting	December 2021	United States, Pennsylvania ... 展开 >> Temple University Hospital Not yet recruiting Philadelphia, Pennsylvania, United States, 19140 Contact: Francine McGonagle, BSN,RN 215-707-2682 Francine.McGonagle@tuhs.temple.edu Contact: Shubhra Srivastava-Malhotra 215-707-0945 Shubhra.Srivastava-Malhotra@tuhs.temple.edu Principal Investigator: Jonathan A Galli, MD Sub-Investigator: Gerard J Criner, MD Sub-Investigator: Patrick Mulhall, MD Sub-Investigator: Kartik Shenoy, MD Sub-Investigator: James Brown, MD Sub-Investigator: Thomas Rogers, PhD 收起 <<
NCT02182154	Healthy	Phase 1	Completed	-	-
NCT00805194	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	-
NCT01022853	Neoplasms	Phase 1	Completed	-	Italy ... 展开 >> 1230.7.39002 Boehringer Ingelheim Investigational Site Ancona, Italy 1230.7.39001 Boehringer Ingelheim Investigational Site Milano, Italy 收起 <<
NCT00805194	-		Completed	-	-
NCT02182245	Genital Neoplasms, Female	Phase 1	Completed	-	-
NCT00876460	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Japan ... 展开 >> 1199.29.002 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 1199.29.001 Boehringer Ingelheim Investigational Site Osaka-Sayamashi, Osaka, Japan 收起 <<
NCT02182063	Prostatic Neoplasms	Phase 2	Completed	-	-
NCT01024920	Carcinoma, Renal Cell	Phase 2	Active, not recruiting	February 15, 2019	Hungary ... 展开 >> University of Pecs Medical School, Dept. of Oncotherapy Pecs, Hungary, 7624 Poland Ziemia Lubelska Oncological Center, Lublin Lublin, Poland, 20-099 Onco.Cent. - Instit. of Maria Sklodowskiej-Curie Warszawa, Poland, 02-781 Romania Military Central Clinical Emergency Hospital Bucharest, Romania, 010825 Sf. Nectarie Oncology Center, Craiova Craiova, Romania, 200347 ONCOLAB SRL, Craiova Craiova, Romania, 200385 Ukraine Municipal Establishment Cherkasy Oncology Centre Cherkasy, Ukraine, 18009 Bukovynsk State Medical University Chernivtsi, Ukraine, 58013 City Clinical Hospital #4, Dnipropetrovsk State Medical Academy Dnipropetrovks, Ukraine, 49102 CI of LRC Lviv Onco.Reg.Treat.&Diag.Cent. Lviv, Ukraine, 79031 Uzhgorod National University, Oncology Centre Uzhgorod, Ukraine, 88000 United Kingdom Addenbrooke's Hospital Cambridge, United Kingdom, CB2 0QQ Beatson West of Scotland Cancer Centre Glasgow, United Kingdom, G12 0YN Surrey Cancer Research Institute Guildford, United Kingdom, GU2 7WG St James's University Hospital Leeds, United Kingdom, LS9 7TF 收起 <<
NCT01380782	Glioblastoma ... 展开 >>Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908-4324 收起 <<
NCT01022853	-		Completed	-	-
NCT01335464	Pulmonary Fibrosis	Phase 3	Completed	-	-
NCT02835833	Renal Cell Carcinoma ... 展开 >> Colorectal Adenocarcinoma Non-squamous Non-small Cell Lung Cancer Platinum-refractory Ovarian Carcinoma Cervical Carcinoma 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294 收起 <<
NCT01136174	Idiopathic Pulmonary Fibrosis	Phase 2	Completed	-	Japan ... 展开 >> 1199.31.002 Boehringer Ingelheim Investigational Site Bunkyo-ku,Tokyo, Japan 1199.31.004 Boehringer Ingelheim Investigational Site Hamamatsu, Shizuoka, Japan 1199.31.008 Boehringer Ingelheim Investigational Site Himeji, Hyogo, Japan 1199.31.006 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1199.31.007 Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan 1199.31.005 Boehringer Ingelheim Investigational Site Seto, Aichi, Japan 1199.31.001 Boehringer Ingelheim Investigational Site Shimotsuke,Tochigi, Japan 1199.31.003 Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan 收起 <<
NCT01380782	-		Completed	-	-
NCT00998296	Neoplasms	Phase 1	Completed	-	France ... 展开 >> 1239.14.3301A Boehringer Ingelheim Investigational Site Villejuif Cedex, France 收起 <<
NCT00876460	-		Completed	-	-
NCT01335477	-		Completed	-	-
NCT01314105	Ovarian Neoplasms ... 展开 >> Peritoneal Neoplasms 收起 <<	Phase 1	Completed	-	Spain ... 展开 >> 1199.119.34001 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.119.34002 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.119.34003 Boehringer Ingelheim Investigational Site L'Hospitalet de Llobregat, Spain 收起 <<
NCT01441297	Small Cell Lung Cancer ... 展开 >> Small Cell Lung Cancer Recurrent 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 收起 <<
NCT01335477	Pulmonary Fibrosis	Phase 3	Completed	-	-
NCT00998296	-		Completed	-	-
NCT02182232	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	-
NCT01683682	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Germany ... 展开 >> Krankenhaus Großhansdorf Großhansdorf, Germany, D-22927 Klinikum Kassel GmbH Kassel, Germany, D-34125 收起 <<
NCT01329549	Ovarian Neoplasms	Phase 1	Terminated	-	Japan ... 展开 >> 1199.117.003 Boehringer Ingelheim Investigational Site Akashi, Hyogo, Japan 1199.117.002 Boehringer Ingelheim Investigational Site Chuo-ku,Tokyo, Japan 1199.117.001 Boehringer Ingelheim Investigational Site Hidaka, Saitama, Japan 收起 <<
NCT01666600	Glioblastoma Multiforme	Phase 1 Phase 2	Terminated(Interim Analysis fo... 展开 >>r Feasibility) 收起 <<	-	Germany ... 展开 >> University Hospital Heidelberg, Department of Neurooncology Heidelberg, Baden-Württemberg, Germany, 69120 University Hospital Heidelberg, Department of Pharmacology Heidelberg, Baden-Württemberg, Germany, 69120 收起 <<
NCT01314105	-		Completed	-	-
NCT01346540	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Italy ... 展开 >> 1199.82.39004 Boehringer Ingelheim Investigational Site Milano, Italy Netherlands 1199.82.3102 Boehringer Ingelheim Investigational Site Maastricht, Netherlands Spain 1199.82.3401 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.82.3406 Boehringer Ingelheim Investigational Site Madrid, Spain 1199.82.3410 Boehringer Ingelheim Investigational Site Málaga, Spain United Kingdom 1199.82.4401 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.82.4402 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 收起 <<
NCT02558387	Recurrent or Metastatic Saliva... 展开 >>ry Gland Cancer of the Head and Neck 收起 <<	Phase 2	Unknown	January 2017	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT01329549	-		Terminated	-	-
NCT01335464	-		Completed	-	-
NCT01684111	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Germany ... 展开 >> Klinikum Kassel GmbH Kassel, Hessen, Germany, 34125 LungenClinic Großhansdorf GmbH Großhansdorf, Germany, 22927 Thoraxklinik Universitätsklinikum Heidelberg Heidelberg, Germany, D-69126 Klinikum der Universität München München, Germany, D-80336 收起 <<
NCT02182141	Multiple Myeloma	Phase 1	Completed	-	-
NCT01610869	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer 收起 <<	Phase 2	Active, not recruiting	January 2019	United Kingdom ... 展开 >> Kent Oncology Centre Maidstone, Kent, United Kingdom Beatson West of Scotland Cancer Centre Glasgow, Scotland, United Kingdom Velindre Hospital Cardiff, Wales, United Kingdom Royal United Hospital Bath, United Kingdom Addenbrookes Hospital Cambridge, United Kingdom Royal Derby Hospital Derby, United Kingdom Royal Surrey County Hospital Guildford, United Kingdom St James's University Hospital Leeds, United Kingdom Clatterbridge Centre for Oncology Liverpool, United Kingdom Mount Vernon Hospital London, United Kingdom Royal Marsden Hospital London, United Kingdom St Bartholomew's Hospital London, United Kingdom University College London Hospital (UCLH) London, United Kingdom Christie Hospital Manchester, United Kingdom Churchill Hospital Oxford, United Kingdom Wexham Park Hospital Slough, United Kingdom 收起 <<
NCT02496585	Lung Cancer L... 展开 >>ung Metastases 收起 <<	Phase 2	Recruiting	July 2019	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Raymond Mak, MD 617-632-3591 United States, New Jersey Memorial Sloan Kettering Cancer Center at Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Andreas Rimner, MD 212-639-6025 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Andreas Rimner, MD 212-639-6025 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Andreas Rimner, MD 212-639-6025 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Andreas Rimner, MD 212-639-6025 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Andreas Rimner, MD 212-639-6025 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Andreas Rimner, MD 212-639-6025 Contact: Jamie Chaft, MD 646-888-4545 Principal Investigator: Andreas Rimner, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Andreas Rimner, MD 212-639-6025 Contact: Jamie Chaft, MD 646-888-4545 Principal Investigator: Andreas Rimner, MD United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Daniel Gomez, MD 713-563-8446 Principal Investigator: Daniel Gomez, MD 收起 <<
NCT01346540	-		Completed	-	-
NCT01619085	Idiopathic Pulmonary Fibrosis	Phase 3	Active, not recruiting	March 4, 2019	-
NCT02182219	Prostatic Neoplasms	Phase 1	Completed	-	-
NCT02182102	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	-
NCT01951846	Malignant Solid Tumour	Phase 1	Completed	-	Germany ... 展开 >> Klinik für Tumorbiologie, Abteilung Internistische Onkologie Freiburg, Germany, 79106 收起 <<
NCT02152059	Small Cell Lung Cancer ... 展开 >> Platinum-sensitive 收起 <<	Phase 2	Withdrawn(contract issues)	-	Canada, Alberta ... 展开 >> Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 收起 <<
NCT02278978	Urothelial Carcinoma	Phase 2	Unknown	March 2016	Taiwan ... 展开 >> Chia-Chi Lin Taipei, Taiwan 收起 <<
NCT02182206	Tumors	Phase 1	Completed	-	-
NCT01349296	Solid Tumors	Phase 1	Completed	-	Germany ... 展开 >> University Hospital of Cologne Cologne, NRW, Germany, 50937 收起 <<
NCT01485874	Ovarian Cancer	Phase 1	Terminated(Funding withdrawn d... 展开 >>ue to drug unavailability) 收起 <<	-	United States, Indiana ... 展开 >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT01669798	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Peritoneal Cancer 收起 <<	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Duke Cancer Institute Durham, North Carolina, United States, 27710 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Virginia Oncology Associates Norfolk, Virginia, United States, 23502 收起 <<
NCT02182128	Tumors	Phase 1	Completed	-	-
NCT01619085	-		Active, not recruiting	-	-
NCT02389764	Breast Cancer	Phase 2	Terminated(Slow Accrual)	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02182076	Healthy	Phase 1	Completed	-	-
NCT01669798	-		Completed	-	-

A549	2/5 μM	Function Assay	24 h	has a general EMT reversal effect	26061747
A549	0.01–5 μM	Function Assay	24 h	induces SFTPD mRNA expression dose dependently	25843005
A549	0.01–5 μM	Function Assay	72 h	enhances SP-D protein expression in a dose-dependent manner at concentrations of up to 5 μM	25843005
A549	5 μM	Function Assay	0-1 h	increases AP-1 activation after 30 min	25843005
H1703		Growth Inhibition Assay		IC50=0.05 μM	23729403
Hep3B	0-20 μM	Cell Viability Assay	48 h	decreases cell viability dose dependently	24657398
Hep3B	0-20 μM	Apoptosis Assay	48 h	induces cell apoptosis dose dependently	24657398
HepG2	0-20 μM	Cell Viability Assay	48 h	decreases cell viability dose dependently	24657398
HepG2	0-20 μM	Apoptosis Assay	48 h	induces cell apoptosis dose dependently	24657398
HuH7	0-20 μM	Cell Viability Assay	48 h	decreases cell viability dose dependently	24657398
HuH7	0-20 μM	Apoptosis Assay	48 h	induces cell apoptosis dose dependently	24657398
Mia-Paca2	2/5 μM	Function Assay	24 h	has a general EMT reversal effect	26061747
PLC5	0-20 μM	Cell Viability Assay	48 h	decreases cell viability dose dependently	24657398
PLC5	0-20 μM	Apoptosis Assay	48 h	induces cell apoptosis dose dependently	24657398
SK-Hep1	0-20 μM	Cell Viability Assay	48 h	decreases cell viability dose dependently	24657398
SK-Hep1	0-20 μM	Apoptosis Assay	48 h	induces cell apoptosis dose dependently	24657398
SKOV3	5 µM	Function Assay	24 h	induces a significant increase in the promoter activities of E-cad, CDH1, and CDH3	26061747
T24	2/5 μM	Function Assay	24 h	has a general EMT reversal effect	26061747

尼达尼布 /Nintedanib {[allProObj[0].p_purity_real_show]}

Nintedanib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Nintedanib 质控信息

Nintedanib 生物活性

Nintedanib 细胞研究

Nintedanib 动物研究

Nintedanib 临床研究

Nintedanib 参考文献

Nintedanib 实验方案

Nintedanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1, IC50:34 nM
VEGFR3	VEGFR3, IC50:13 nM
VEGFR2	VEGFR2, IC50:13 nM
PDGFRβ	PDGFRβ, IC50:65 nM
PDGFRα	PDGFRα, IC50:59 nM
FGFR2	FGFR2, IC50:37 nM
FGFR3	FGFR3, IC50:108 nM
FGFR4	FGFR4, IC50:610 nM
FGFR1	FGFR1, IC50:69 nM

尼达尼布 /Nintedanib {[allProObj[0].p_purity_real_show]}

Nintedanib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Nintedanib 质控信息

Nintedanib 生物活性

Nintedanib 细胞研究

Nintedanib 动物研究

Nintedanib 临床研究

Nintedanib 参考文献

Nintedanib 实验方案

Nintedanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Nintedanib 纯度/质量文件产品仅供科研